Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: Results of prospective study in nonrandomized population of 259 patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069321" target="_blank" >RIV/00216224:14110/13:00069321 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: Results of prospective study in nonrandomized population of 259 patients
Original language description
Background: The purpose was to evaluate the activity and feasibility of CBDCA together with NVBO in 1st line treatment NSCLC patients. Conclusions: The treatment with NVBO and CBDCA was well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů